Valneva Se · EURONEXT:VLA
Valneva — Shareholder Meeting (December 2023)
54 slides from Valneva's shareholder meeting presentation, Dec 20, 2023
Slide 1: 2023 Combined General Meeting Valneva SE
2023 Combined General Meeting Valneva SE December 20, 2023 Nantes
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Valneva is a European company. Information dist
Slide 3: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 4: Proceedings of the Meeting: AGM preliminary formalities
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 5: Preliminary Formalities
Preliminary Formalities Sign attendance sheet (All) Appoint AGM committee (Chair, Observers, Secretary) Validation of the Quorum (Secretary) Documents filed with the AGM committee (Secretary) Agenda (Chairperson) VALNEVA - Combined General Meeting December 20, 2023 5
Slide 6: Proceedings of the Meeting: Introduction
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 7: Proceedings of the Meeting: Company overview
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 8: Valneva Summary and Core Strengths
Valneva Summary and Core Strengths Fully integrated specialty vaccine company focused on development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need Highly specialized and targeted approach to development of unique prophylac
Slide 9: Valneva's R&D Pipeline
Valneva’s R&D Pipeline Overview Development Program Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Next Inflection Point Partners IXCHIQ® / CEPI/ Butantan IXCHIQ®: FDA Approved Expect to launch VLA1553: PRV received early 2024 (LMIC) Chikungunya Primary vaccination VLA153: completion for
Slide 10: IXCHIQ: The World's First Approved Chikungunya Vaccine
IXCHIQ®: The World’s First Approved Chikungunya Vaccine FDA-approved, live-attenuated vaccine with potential additional regulatory approvals in 2024 Pioneering Vaccine Development in an Area of High Unmet Need – Preparing for Success • First chikungunya vaccine to be approved by the FDA – PRV awarde
Slide 11: VLA1553: Clinical Data Highlights
VLA1553: Clinical Data Highlights1,2,5 Live-attenuated CHIKV vaccine demonstrates rapid and long-lasting immunity with a single shot Immunogenicity Data Safety Data 99% Seroresponse3 Rate (SRR) after a single VLA1553 was generally well tolerated among the vaccination >3,600 adults and 754 adoles
Slide 12: Chikungunya Global Market Segments
Chikungunya Global Market Segments Global market for chikungunya vaccines estimated to exceed $500 million per year by 20321 Segments Targeted Directly by Valneva Segments Targeted via Partnership Travelers from Non-Endemic Regions Endemic Region Use Travel vaccine for individuals traveling to areas
Slide 13: Multivalent Recombinant Protein Vaccine Candidate for Lyme Disease
Multivalent Recombinant Protein Vaccine Candidate for Lyme Disease VLA15: The only Lyme disease program in advanced clinical development today Phase 3 study ongoing, sponsored by Pfizer1 and supported by positive results for 1 three Phase 2 clinical trials2,3,4, incl. first pediatric/adolescent data
Slide 14: Phase 3 Efficacy Study Fully Enrolled
Phase 3 Efficacy Study Fully Enrolled Population: ~9000 total participants ≥5 years of age at high risk of Lyme disease (LD) (by residence and occupational/recreational activities) in U.S., Canada and Europe (randomization approx. 1:1 VLA15/Placebo and 2:1 N. America/EU) Primary endpoint: Rate o
Slide 15: VLA1601: Potential to be a Differentiated Zika Virus Vaccine
VLA1601: Potential to be a Differentiated Zika Virus Vaccine Adjuvanted, inactivated whole virus vaccine candidate Zika viral disease Valneva’s vaccine candidate Flaviviral disease transmitted by Aedes mosquitoes1 Highly purified Common flu-like symptoms, lasting between 2 -7 Adjuvanted inac
Slide 16: Proceedings of the Meeting: Business highlights & recent newsflow
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 17: Valneva Continued to Deliver in 2023
Valneva Continued to Deliver in 2023 Chikungunya vaccine IXCHIQ® (VLA1553) FDA approved world’s first chikununya vaccine, IXCHIQ® EMA accepted marketing authorization application for accelerated assessment Health Canada and Anvisa (Brazil) accepted chikungunya vaccine license application for r
Slide 18: Key Upcoming Catalysts and News Flow
Key Upcoming Catalysts and News Flow Chikungunya vaccine EMA, Health Canada and Anvisa (Brazil) approvals expected mid-2024 ACIP recommendation expected Q1 2024 Lyme disease vaccine candidate VLA15 VALOR trial: completion of primary vaccination for Cohort 1 expected H1 2024 Additional news flo
Slide 19: Proceedings of the Meeting: Valneva's governance model
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 20: Transition to a Board of Directors
Transition to a Board of Directors • Shareholders to vote on a potential transition from a two-tier governance model (Supervisory Board and Management Board) to a one-tier model led by a Board of Directors, to further improve the effectiveness and efficiency of the Company’s leadership. • Chair of t
Slide 21: Proceedings of the Meeting: Answers to written questions
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 22: Proceedings of the Meeting: Auditor's reports
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 23: Summary of the Auditors' Reports
Summary of the Auditors’ Reports The Statutory Auditors have performed the procedures that they considered necessary in accordance with the professional guidelines of the French National Institute of Statutory Auditors (Compagnie Nationale des Commissaires aux Comptes) for the purpose of preparing t
Slide 24: Proceedings of the Meeting: Presentation of the resolutions
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 25: Important Note on Resolutions
IMPORTANT NOTE Some of the resolutions shown on the following slides have been summarized. For the full text version, please refer to the “Investors” / “General Meetings” / “December 20, 2023 Combined General Meeting” section of Valneva’s website www.valneva.com. The English resolutions and their En
Slide 26: Resolution 1 - Appointment of Ms. Anne-Marie Salaün as Director
Resolution 1 - Appointment of Ms. Anne-Marie Salaün (preferred name: Graffin) as Director (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting in accordance wi
Slide 27: Resolution 2 - Appointment of Mr. James Edward Connolly as Director
Resolution 2 - Appointment of Mr. James Edward Connolly as Director (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting in accordance with the quorum and majo
Slide 28: Resolution 3 - Appointment of Mr. James Sulat as Director
Resolution 3 - Appointment of Mr. James Sulat as Director (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting in accordance with the quorum and majority requi
Slide 29: Resolution 4 - Appointment of Ms. Kathrin Ute Jansen as Director
Resolution 4 - Appointment of Ms. Kathrin Ute Jansen as Director (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting in accordance with the quorum and majorit
Slide 30: Resolution 5 - Appointment of Bpifrance Participations as Director
Resolution 5 - Appointment of the company Bpifrance Participations as Director (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting in accordance with the quor
Slide 31: Resolution 6 - Appointment of Mr. Thomas Lingelbach as Director
Resolution 6 - Appointment of Mr. Thomas Lingelbach as Director (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting in accordance with the quorum and majority
Slide 32: Resolution 7 - Compensation policy for executive corporate officers
Resolution 7 - Approval of the compensation policy applicable to the executive corporate officers (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting in accor
Slide 33: Resolution 8 - Compensation policy for Board members
Resolution 8 - Approval of the compensation policy applicable to the members of the Board of Directors (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting in
Slide 34: Resolution 9 - Total compensation for Board members
Resolution 9 - Determination of the total compensation allocated to the members of the Board of Directors (subject to adoption of the change in the Company’s governance model) Subject to adoption of resolution 11 below relating to a change in the Company’s governance model, the Shareholders, acting
Slide 35: Resolution 10 - Transactions on own shares
Summary of resolution 10 - Authorization and powers to be given to the Board of Directors for the purpose of allowing the Company to make transactions on its own shares Subject to adoption of resolution 11 relating to a change in the Company’s governance model Authorization to the Company, for a per
Slide 36: Resolution 11 - Changing the governance model
Summary of resolution 11 - Changing the Company’s governance model by establishing a Board of Directors; Consequential amendment to the Company’s Articles of Association The Shareholders, acting in accordance with the quorum and majority requirements applicable to Extraordinary General Meetings, aft
Slide 37: Resolution 12 - Cancel treasury shares
Resolution 12 - Authorization granted to the Board of Directors to cancel treasury shares Subject to adoption of resolution 11 relating to a change in the Company’s governance model, the Shareholders, acting in accordance with the quorum and majority requirements applicable to Extraordinary General
Slide 38: Resolution 13 - Capital increase with preferential subscription rights
Summary of resolution 13 - Grant of authority to the Board of Directors to increase the share capital by issuing ordinary shares or any securities giving access to the capital while maintaining the preferential subscription right of the shareholders Subject to adoption of resolution 11 relating to a
Slide 39: Resolution 14 - Capital increase through public offering
Summary of resolution 14 - Grant of authority to the Board of Directors to increase the capital by issuing ordinary shares or any securities giving access to the capital through a public offering (other than those referred to in Article L. 411-2, 1° of the French Monetary and Financial Code), cancel
Slide 40: Resolution 15 - Capital increase through private placement
Summary of resolution 15 - Grant of authority to the Board of Directors to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company's share capital, with cancellation of preferential subscription rights of the shareholders, through a public
Slide 41: Resolution 16 - Setting the issue price
Summary of resolution 16 - Grant of authority to the Board of Directors in the event of an issue of the Company’s ordinary shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders, to set
Slide 42: Resolution 17 - Capital increase for certain categories of persons
Summary of resolution 17 - Grant of authority to the Board of Directors to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders for the benefit of
Slide 43: Resolution 18 - Increase number of shares issued
Resolution 18 - Grant of authority to the Board of Directors to increase the number of shares to be issued in the case of a capital increase, with or without preferential subscription rights for existing shareholders, within the limit of 15% of the initial issue amount Subject to adoption of resolut
Slide 44: Resolution 19 - Capitalization of reserves
Resolution 19 - Grant of authority to the Board of Directors in order to increase the share capital through the capitalization of reserves, earnings or premium Subject to adoption of resolution 11 relating to a change in the Company’s governance model, the Shareholders, acting in accordance with the
Slide 45: Resolution 20 - Contributions in kind
Summary of resolution 20 - Grant of authority to the Board of Directors to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders, in consideration
Slide 46: Resolution 21 - Maximum aggregate amount of capital increases
Resolution 21 - Maximum aggregate amount of capital increases Subject to adoption of resolution 11 relating to a change in the Company’s governance model, the Shareholders, acting in accordance with the quorum and majority requirements applicable to Extraordinary General Meetings, after having revie
Slide 47: Resolution 22 - Stock options
Summary of resolution 22 - Grant of authority to the Board of Directors for the purpose of granting stock options, through one or more issues, for the benefit of employees and/or corporate officers of the Company and its affiliates, entailing waiver by shareholders of their preferential subscription
Slide 48: Resolution 23 - Issue of free shares
Summary of resolution 23 - Issue of free shares; Delegation of authority to the Board of Directors for this purpose Subject to adoption of resolution 11 relating to a change in the Company’s governance model, the Shareholders authorize the Board of Directors, to proceed through one or more transacti
Slide 49: Resolution 24 - Capital increase reserved for employees
Summary of resolution 24 - Grant of authority to the Board of Directors for the purpose of deciding to carry out a capital increase reserved for employees Subject to adoption of resolution 11 relating to a change in the Company’s governance model, the Shareholders resolve in accordance with the prov
Slide 50: Resolution 25 - Powers for formalities
Resolution 25 - Powers for formalities The Shareholders grant all powers to the holder of an original copy, an excerpt or a copy of these minutes certified as authentic to carry out all necessary processes, filings and formalities or as required by operation of law. VALNEVA - Combined General Meetin
Slide 51: Proceedings of the Meeting: Discussion
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 52: Proceedings of the Meeting: Voting
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 53: Proceedings of the Meeting: Conclusion
Proceedings of the Meeting 1. Welcome 2. AGM preliminary formalities 3. Introduction 4. Company overview 5. Business highlights & recent newsflow 6. Valneva’s governance model 7. Answers to written questions 8. Auditor’s reports 9. Presentation of the resolutions 10. Discussion 11. Voting 12. Conclu
Slide 54: WAvalneva
WAvalneva